APLT:NSD-Applied Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.58

Change

-0.16 (-4.28)%

Market Cap

USD 0.10B

Volume

0.23M

Avg Analyst Target

USD 19.00 (+430.73%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Applied Therapeutics Inc (APLT) Stock Analysis:
Based on the Applied Therapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Applied Therapeutics Inc is USD 19.00 over the next 12 months. Applied Therapeutics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Applied Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Applied Therapeutics Inc’s stock price was USD 3.58. Applied Therapeutics Inc’s stock price has changed by -0.43% over the past week, -6.05% over the past month and -82.84% over the last year.

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in heal ...Read More

Company Website : https://www.appliedtherapeutics.com

Address : 545 Fifth Avenue, New York, NY, United States, 10017

Employees : 27

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.90

52 Week High : 29.80

Short Ratio : 9.61

52 Week Low : 3.60

Shorted Shares : 1,061,284

200 Day Moving Average : 15.83

Shorted Shares Previous Month : 1,052,018

50 Day Moving Average : 9.96

Shares Held By Insiders : 21.42%

Short Percentage : 5.98%

Shares Held by Institutions : 78.32%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

 USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

 USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

 USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

 USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

 USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

 USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

 USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

 USD17.76B N/A N/A

ETFs Containing APLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.00% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.00% 1% F N/A N/A
Trailing 12 Months  
Capital Gain -82.84% 8% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.84% 8% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 21.52% 60% D- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.52% 60% D- 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 103.87% 25% F 15% F
Risk Adjusted Return 20.72% 50% F 37% F
Market Capitalization 0.10B 32% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.96 50% F 41% F
Price / Cash Flow Ratio -1.32 17% F 57% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -107.69% 25% F 17% F
Return on Invested Capital -163.41% 8% F 4% F
Return on Assets -52.52% 11% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.61 10% F 6% F
Short Percent 5.98% 35% F 28% F
Beta 0.90 67% D+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.